This early-stage trial tests a vaccine called PEP-CMV in 30 children and young adults (ages 3–35) whose medulloblastoma or malignant glioma has come back. The vaccine is designed to train the immune system to attack tumor cells that carry a common virus protein (CMV). Participant…
Phase: PHASE1 • Sponsor: Daniel Landi • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC